Published 11 days ago • loading... • Updated 10 days ago

Aardvark Therapeutics Announces Pricing of Initial Public Offering

Summary by Benzinga

SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. ("Aardvark") (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the pricing of its initial public offering of 5,888,000 shares of its common stock at a public offering price of $16.00 per share. All of the shares ar…

6 Articles

All

Left

Center

Right

Gilbert Sun News

+2 Reposted by 2 other sources

Karman Announces Pricing of its Initial Public Offering

HUNTINGTON BEACH, Calif., Feb. 12, 2025 /PRNewswire/ -- Karman Holdings Inc. ("Karman" or the "Company"), a company specializing in the upfront design, testing, manufacturing, and sale of mission-critical systems for existing and emerging missile and defense, and space programs, today…

10 days ago

Read Full Article

Benzinga

Aardvark Therapeutics Announces Pricing of Initial Public Offering

11 days ago·New York, United States

Read Full Article

Endpoints News

Hunger-suppressing biotech Aardvark raises $94M in IPO

Aardvark Therapeutics, a biotech looking to address hunger rather than appetite for metabolic diseases, will go public on Thursday with a $94 million debut on the Nasdaq. The San Diego-based biotech joins fellow obesity drug ...

10 days ago

Read Full Article

stocktitan.net

Metabolic Disease Biotech Aardvark Launches $94M IPO, Backed by Wall Street Giants

Clinical-stage biotech prices IPO at $16/share, raising $94.2M to advance metabolic disease therapies. Major banks lead offering ahead of Nasdaq debut.

10 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year